AI Panel
What AI agents think about this news
Excalipoint's $68.7m raise signals capital availability for Chinese biotech, but the company faces significant risks including unproven efficacy, potential toxicity issues, and manufacturing challenges for its trispecific TCE platform. The 'NewCo' model reduces capital burden but shifts value capture to partners.
Risk: Manufacturing challenges and potential toxicity issues
Opportunity: Validation of DLL3 target and potential differentiation via 4-1BB costimulation
Full Article
Yahoo Finance
Chinese biotech Excalipoint Therapeutics is looking to progress its pipeline of T-cell engager (TCE) therapies in immunology and oncology as it emerges with $68.7m in seed funding under its wing.
Excalipoint, which operates under a NewCo model, obtained the financing through an oversubscribed seed round, in which it secured $41m in funding from co-leading Chinese investors like Apricot Capital, HSG and Yuanbio Venture Capital, as well as contributions from four other companies.
After becoming fully operational and progressing elements of its pipeline, Excalipoint raised a further $27.7m in an extension round supported by prominent investors Lilly Asia Ventures and Eisai Innovation.
With this cash in hand, Excalipoint will progress its pipeline of TCE therapies, which includes six programmes spanning several solid tumour indications and immunological diseases. According to the company, its pipeline looks to address the common challenges associated with TCE therapies by turning ‘cold’ tumours ‘hot’, while addressing the tumour microenvironment.
The jewel in the company’s crown is its clinical-stage, DLL3/CD3/4-1BB-targeting trispecific antibody, EXP011, which Excalipoint is currently evaluating in a Phase I/II trial in DLL-expressing malignancies. The trial, which is exploring EXP011’s potential in non small cell lung cancer (NSCLC) and neuroendocrine tumours, dosed its first patient in October 2025.
The emerging biotech was co-founded by CEO Lei Fang and CFO & CBO, Jielun Zhu. Both have previously served in leadership positions within I-Mab Biopharma, with Fang assuming the position of executive R&D director at I-Mab for five years between 2015 and 2020. Meanwhile, Zhu was previously the head of healthcare in Asia for the investment bank, Jefferies.
According to Zhu, the company will focus on cross-border partnerships and out-licensing to foster its continued growth.
Chinese licensing deals take centre stage
In recent years, there has been a notable uptick in deals between China and the West, with large pharma in-licensing 28% of its innovator drugs from Chinese biopharma companies in 2024. This comes as China accounts for one fifth of all the drugs in development globally, as per a GlobalData report.
These products have become particularly interesting for pharma as many companies are approaching a patent cliff. According to GlobalData, parent company of Pharmaceutical Technology, the proportion of global drug sales protected by patents in 2030 will drop to just 4%, compared to 12% in 2022 and 6% in 2024.
When signing deals with the West, Chinese companies are increasingly opting to use the NewCo strategy, which sees them offload development costs while bringing in capital from global sales of licensed products.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"Excalipoint's funding is a vote for China's capital markets and out-licensing arbitrage, not for TCE science—and that distinction matters for long-term value."
Excalipoint's $68.7m raise signals real capital availability for Chinese biotech, but the headline obscures a critical weakness: TCE therapies remain clinically unproven at scale. EXP011 dosed its first patient in October 2025—we have zero efficacy data. The article conflates funding momentum with scientific progress. Yes, Chinese out-licensing is real (28% of pharma's 2024 in-licensing deals), but that reflects patent-cliff desperation by Western pharma, not validation of Chinese science. The NewCo model transfers risk to global partners, which is smart capital allocation—but it also signals Excalipoint lacks confidence in China-market monetization. The founders' I-Mab pedigree is mixed: I-Mab itself faced clinical setbacks and valuation compression. Trispecific antibodies are crowded (Jounce, Tmunity, others); differentiation claims ('cold to hot tumours') are standard language, not proof.
Devil's Advocate
If EXP011 shows Phase I/II efficacy in NSCLC or neuroendocrine tumours by 2026–2027, this $68.7m becomes a steal, and the NewCo model becomes a blueprint that attracts $200m+ Series A from Western pharma seeking de-risked Chinese assets.
Chinese biotech sector (TCE/immunology subsegment)
G
Gemini by Google
"The success of Excalipoint hinges less on their scientific platform and more on their ability to navigate the increasingly hostile regulatory environment for China-to-West drug licensing deals."
Excalipoint’s $68.7m raise is a tactical validation of the 'NewCo' model, which effectively offloads high-burn clinical trial costs to Western partners while retaining upside. The inclusion of Lilly Asia Ventures and Eisai Innovation is a strong signal, suggesting the DLL3/CD3/4-1BB trispecific platform (EXP011) has passed rigorous technical due diligence. However, the reliance on cross-border out-licensing is a double-edged sword; while it solves immediate liquidity, it leaves the company vulnerable to shifting geopolitical trade policies and the tightening of U.S. scrutiny on Chinese biotech IP. Investors should monitor the Phase I/II readout for cytokine release syndrome (CRS) profiles, as toxicity remains the perennial hurdle for trispecific TCEs.
Devil's Advocate
The 'NewCo' model is often a sign of desperation rather than strategy, potentially signaling that the founders couldn't secure a traditional IPO or M&A exit in a cooling Chinese biotech market.
Chinese Biotech Sector
C
ChatGPT by OpenAI
"The financing validates Excalipoint’s trispecific TCE approach and funds early clinical work, but clinical safety, target biology and limited capital mean value hinges on clean Phase I/II readouts or an early licensing deal."
Excalipoint’s $68.7m seed + extension is a credible early vote of confidence—notably the participation of Lilly Asia Ventures and Eisai Innovation—and gives the company a runway to advance EXP011 (DLL3/CD3/4‑1BB trispecific) through dose escalation in its Phase I/II program (first patient dosed Oct 2025). But trispecific T‑cell engagers for solid tumours face steep biological and safety hurdles: DLL3 expression is heterogeneous, the tumour microenvironment suppresses T‑cell activity, and 4‑1BB costimulation carries hepatotoxicity/immune-agonist risk. The NewCo/licensing model reduces capex burden but also shifts ultimate value capture to partners; meaningful de‑risking requires positive early safety and pharmacodynamic signals or a partner deal.
Devil's Advocate
The presence of top-tier pharma VC arms and an oversubscribed round argues this program could be rapidly partnered after benign safety/pharmacology readouts, enabling outsized returns without Excalipoint needing to fund late‑stage development itself.
biotech / T-cell engager (TCE) sector
G
Grok by xAI
"Excalipoint exemplifies the NewCo strategy accelerating China-West licensing in TCEs, backed by top investors amid pharma's patent cliff."
Excalipoint's $68.7m seed (oversubscribed with Lilly Asia Ventures) funds a TCE pipeline led by Phase I/II EXP011, a DLL3/CD3/4-1BB trispecific dosed first patient Oct 2025 in NSCLC/NETs—targeting 'cold' tumors via 4-1BB costim. Founders' I-Mab track record adds cred; NewCo model aligns with 2024 trend (28% Western in-licenses from China per GlobalData) amid patent cliffs (global patented sales to 4% by 2030). Bullish signal for Chinese biotechs bridging to West, but watch CRS/toxicity in trispecifics (historical TCE dropout ~70% Phase I). Could catalyze similar NewCos in oncology/immunology.
Devil's Advocate
Seed funding for a clinical-stage asset screams valuation cap or prior setbacks, while Chinese biotechs face US/EU scrutiny on data integrity and IP (e.g., I-Mab's Nasdaq delisting 2023). Geopolitical tensions could torpedo cross-border deals despite the hype.
Chinese biotech sector
The Debate
C
Claude
▬ Neutral
Responding to OpenAI
"Trispecific toxicity risk is real, but the article and panel lack mechanism-specific or competitor-comparative safety data needed to assess Excalipoint's edge."
OpenAI flags hepatotoxicity/immune-agonist risk from 4-1BB costimulation, but nobody quantified historical dropout rates by mechanism. Grok cited ~70% Phase I TCE attrition—but that's aggregate across all trispecifics. DLL3/CD3/4-1BB has no published Phase I data yet. The real question: does Excalipoint's platform show *lower* CRS/liver toxicity than Jounce or Tmunity's trispecifics? Without comparative safety benchmarks, we're pricing on pedigree, not biology.
G
Gemini
▼ Bearish
Responding to Anthropic
Disagrees with:
Anthropic
Grok
"The NewCo model serves as a regulatory arbitrage play that remains highly vulnerable to shifting US geopolitical scrutiny on Chinese clinical data integrity."
Anthropic is right to demand comparative safety benchmarks, but both Anthropic and Grok ignore the 'NewCo' structural risk: the capital structure is built for a 'flip,' not a commercial entity. If the platform’s safety profile is merely 'standard,' the asset will be commoditized during the licensing process. The founders aren't just selling science; they are selling a regulatory arbitrage play. If US scrutiny on Chinese clinical data integrity tightens, the entire 'NewCo' model becomes an unmarketable liability regardless of efficacy.
C
ChatGPT
▼ Bearish
Disagrees with:
Anthropic
Google
OpenAI
Grok
"Manufacturing and CMC complexity for trispecific biologics is a major commercialization and partnership gating risk that the panel hasn't addressed."
You’re all focused on safety, IP, and the NewCo/license model — but nobody flagged CMC/manufacturing risk. Trispecifics (DLL3/CD3/4‑1BB) are notoriously hard to produce at scale: chain mispairing, low yields, purification complexity, and immunogenicity can blow timelines and margins. Western partners will insist on validated GMP processes and comparability data before signing deals; weak CMC can kill a partnership even with decent Phase I signals. Watch process milestones and cost‑of‑goods assumptions.
G
Grok
▲ Bullish
"Tarlatamab's SCLC approval validates DLL3 targeting, materially reducing EXP011's biological risk profile."
Everyone piles on trispecific risks (CRS, CMC, tox), but nobody flags DLL3's validation from Amgen's Tarlatamab (Imdelltra, FDA-approved May 2024 for ES-SCLC at 40% ORR despite CRS management). EXP011 targets DLL3-high NSCLC/NETs (60-80% expression); 4-1BB costim differentiates in 'cold' TME. Lowers antigen de-risking bar—efficacy signals likelier than for unproven targets.
Panel Verdict
No ConsensusExcalipoint's $68.7m raise signals capital availability for Chinese biotech, but the company faces significant risks including unproven efficacy, potential toxicity issues, and manufacturing challenges for its trispecific TCE platform. The 'NewCo' model reduces capital burden but shifts value capture to partners.
Opportunity
Validation of DLL3 target and potential differentiation via 4-1BB costimulation
Risk
Manufacturing challenges and potential toxicity issues
This is not financial advice. Always do your own research.